Literature DB >> 29346209

The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.

Linda Shore-Lesserson1, Robert A Baker2, Victor A Ferraris3, Philip E Greilich4, David Fitzgerald5, Philip Roman6, John W Hammon7.   

Abstract

Despite more than a half century of "safe" cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation therapy for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiologists, and the American Society of Extracorporeal Technology developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation therapy for CPB using the available evidence. To identify relevant evidence, a systematic review was outlined and literature searches were conducted in PubMed using standardized medical subject heading (MeSH) terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts, which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published before 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Recommendations were written in the three following areas: (1) heparin dosing and monitoring for initiation and maintenance of CPB; (2) heparin contraindications and heparin alternatives; and (3) reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and to expand on the evidence base on the topic of anticoagulation therapy for CPB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29346209     DOI: 10.1213/ANE.0000000000002613

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  Anticoagulation Monitoring for Perioperative Physicians.

Authors:  Cheryl L Maier; Roman M Sniecinski
Journal:  Anesthesiology       Date:  2021-10-01       Impact factor: 8.986

2.  Complement activation during cardiopulmonary bypass and association with clinical outcomes.

Authors:  Rengina Kefalogianni; Farah Kamani; Mihaela Gaspar; T C Aw; Jackie Donovan; Mike Laffan; Matthew C Pickering; Deepa J Arachchillage
Journal:  EJHaem       Date:  2022-01-13

3.  Catastrophic Intracardiac Thrombosis During Emergency Repair of an Expanding Aortic Pseudoaneurysm: A Case Report.

Authors:  Ratna Vadlamudi; Jay Chan; Roman M Sniecinski
Journal:  A A Pract       Date:  2019-11-01

4.  A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients.

Authors:  Gregory A Nuttall; Mark M Smith; Bradford B Smith; Jon M Christensen; Paula J Santrach; Hartzell V Schaff
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-12-22       Impact factor: 1.889

5.  Anticoagulation Management and Heparin Resistance During Cardiopulmonary Bypass: A Survey of Society of Cardiovascular Anesthesiologists Members.

Authors:  Roman M Sniecinski; Elliott Bennett-Guerrero; Linda Shore-Lesserson
Journal:  Anesth Analg       Date:  2019-08       Impact factor: 5.108

6.  The Effect of Cell Salvage on Bleeding and Transfusion Needs in Cardiac Surgery.

Authors:  Frixos Tachias; Evangelia Samara; Anastasios Petrou; Agathi Karakosta; Stavros Siminelakis; Efstratios Apostolakis; Petros Tzimas
Journal:  Anesthesiol Res Pract       Date:  2022-09-01

7.  Barriers and facilitators to implementing evidence based bleeding management in Australian Cardiac Surgery Units: a qualitative interview study analysed with the theoretical domains framework and COM-B model.

Authors:  Bronwyn L Pearse; Samantha Keogh; Claire M Rickard; Yoke L Fung
Journal:  BMC Health Serv Res       Date:  2021-06-05       Impact factor: 2.655

8.  Erroneous Activated Coagulation Time During Atrial Flutter Ablation.

Authors:  Sheldon Goldstein; Jazmin Juarez; Agathe Streiff
Journal:  Case Rep Anesthesiol       Date:  2020-01-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.